Telix Pharmaceuticals found enough demand for its convertibles notes to upsize the deal by $50 million to $650 million overnight, in what should be the biggest healthcare convertibles deal in Asia Pacific in three years.
Telix boss Christian Behrenbruch says the company is just getting started. Simon Schulter
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
